EVG.L Regulatory News (EVG)

7 June 2022

Evgen Pharma plc

Notice of Results

Evgen Pharma plc (AIM: EVG or the "Company"), the clinical stage drug development company developing sulforaphane-based medicines for the treatment of multiple diseases, will be announcing its audited results for the year ended 31 March 2022, on Wednesday, 8 June 2022.

-Ends-

For more information please contact:

About Evgen Pharma plc

Evgen Pharma is a clinical stage drug development company developing sulforaphane-based medicines for the treatment of multiple diseases. The Company's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. 

The Company's lead asset, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin and has undergone clinical trials for oestrogen-positive (ER+) metastatic breast cancer. It will be entering the clinic in glioma/glioblastoma later in 2022. In September 2021 the FDA granted Orphan Drug status to SFX-01 in malignant glioma.

The Company also has a wide number of collaborations with leading academic centres in the UK, Europe and AsiaPac as part of the continuing strategy to build the data set of safety and efficacy around the compound. With respect to non-core areas, Evgen signed an outlicensing deal with JuvLife, the dietary products and functional foods division of Juvenescence Ltd, for the development of a naturally-sourced sulforaphane nutritional health supplement, stabilised using Evgen's Sulforadex® technology.

The Company commenced operations in January 2008 and has its headquarters and registered office at Alderley Park, Cheshire. It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG. 

For further information, please visit: www.evgen.com